Rapport Therapeutics, Inc. (RAPP) Current Ratio
- Current ratio · latest quarter: Value 15.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 15.72× | Current assets / current liabilities. $446.86M ÷ $28.42M ≈ 15.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 446.86M USD | Assets, Current |
| Current obligations | 28.42M USD | Liabilities, Current |
| Cash and equivalents | 63.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 293.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 2.80M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $446.86M | $28.42M | $63.61M | (m) | $293.00K | (m) | $2.80M | (m) | 15.72× |
| 2026-03-31 | $484.69M | $17.90M | $78.06M | (m) | $58.00K | (m) | $6.56M | (m) | 27.08× |
| 2025-12-31 | $498.56M | $19.05M | $52.65M | (m) | $0.00 | (m) | $4.19M | (m) | 26.17× |
| 2025-09-30 | $520.66M | $14.32M | $251.36M | (m) | (m) | (m) | $3.23M | (m) | 36.37× |
| 2025-06-30 | $270.24M | $11.88M | $55.07M | (m) | (m) | (m) | $3.18M | (m) | 22.75× |
| 2025-03-31 | $290.97M | $9.38M | $57.60M | (m) | (m) | (m) | $2.14M | (m) | 31.01× |
| 2024-12-31 | $309.80M | $8.77M | $56.80M | (m) | (m) | (m) | $1.95M | (m) | 35.34× |
| 2024-09-30 | $325.94M | $7.10M | $39.31M | (m) | (m) | (m) | $1.32M | (m) | 45.91× |
| 2024-06-30 | $340.67M | $8.10M | $110.16M | (m) | (m) | (m) | $1.88M | (m) | 42.08× |
| 2023-12-31 | $150.87M | $8.80M | $70.17M | (m) | (m) | (m) | $2.50M | (m) | 17.14× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |